Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of recombinant human PH20 to preparation of medicines used for treating thyroid-associated oculopathy

A technology for thyroid and eye diseases, applied in the field of biopharmaceuticals

Inactive Publication Date: 2018-12-07
EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At present, there is no research on recombinant human PH20 in the field of thyroid-associated ophthalmopathy, and there is no relevant report on the use of recombinant human PH20 to solve the problems of TED patients with extraocular muscle edema in the acute phase and extraocular muscle fibrosis in the chronic phase

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of recombinant human PH20 to preparation of medicines used for treating thyroid-associated oculopathy
  • Application of recombinant human PH20 to preparation of medicines used for treating thyroid-associated oculopathy
  • Application of recombinant human PH20 to preparation of medicines used for treating thyroid-associated oculopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0109] 1. Materials and methods

[0110] (1) Reagents and antibodies

[0111] High glucose DMEM medium (Gibco 11965092), recombinant human PH20 (Abcam ab132258), recombinant human IGF-1 (R&D 291-G1-200), recombinant human TGF-β1 (PeproTech 100-21), rabbit anti-human α-SMA (Abcam ab5694), mouse anti-human Vimentin (Abcam ab8978), donkey anti-rabbit-488 (Invitrogen A21206), donkey anti-mouse Cy3 (Jackson ImmunoResearch, 715165150), TRIZOL (Life 135306), reverse transcription kit (TAKARARR047A ), fluorescent quantitative PCR kit (TAKARA RR420A), high-fidelity PCR enzyme (TAKARA R040A), hyaluronic acid detection kit (Cloud-Clone CEA182Ge), type I collagen detection kit (Abcam ab210966), BrdU detection kit ( Roche 11647229001)

[0112] (2) Primary culture of fibroblasts

[0113] During orbital decompression, 5*5*5mm of muscle tissue was cut from the patient’s extraocular muscle belly 3 , and then immediately put it into the culture medium without FBS, and store it in the refrig...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the application of recombinant human PH20 to preparation of medicines used for treating thyroid-associated oculopathy, especially to the application of recombinant human PH20to preparation of medicines used for treating acute extraocular muscle oedema and chronic extraocular muscle fibrosis caused by thyroid-associated oculopathy, belonging to the field of bio-pharmaceuticals. Experimental results of the invention prove that the extraocular muscle fibroblasts of patients with thyroid-associated oculopathy have the ability of secreting hyaluronic acid, and the recombinant human PH20 can significantly degrade the hyaluronic acid secreted by the fibroblasts; and the recombinant human PH20 can degradehyaluronic acid, solve the problem of edema in an acute phase, and significantly inhibit the proliferation and differentiation of fibroblasts in the presence of the pathogenic factor IGF-1 so as to inhibit fibrosis. The invention provides a novel countermeasure and means for the treatment of thyroid-related oculopathy.

Description

technical field [0001] The invention belongs to the field of biopharmaceuticals, and relates to the use of recombinant human PH20 (also known as rHuPH20) in the preparation of drugs for the treatment of thyroid-related ophthalmopathy, especially the use of recombinant human PH20 in the preparation and treatment of thyroid-related ophthalmopathy caused by acute phase extraocular muscle edema and chronic phase ocular muscle edema. Use in drugs for extrinsic muscle fibrosis. Background technique [0002] The information disclosed that thyroid-associated eye disease (Thyroid Eye Disease, hereinafter referred to as "TED") is an autoimmune disease involving the orbit and surrounding tissues, with inflammation and edema in the active phase and soft tissue fibrosis in the inactive phase as the main manifestations. The most common orbital disease in adults. Studies have shown that TED is often associated with Graves' disease, with an annual incidence of about 16 / 100,000 females and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/47A61P27/02A61P7/10
CPCA61K38/47C12Y302/01035
Inventor 马睿琦程云李倩钱江吴继红王中峰袁一飞任慧郭洁甘路
Owner EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com